Docetaxel in Patients with Metastatic Breast Cancer a Phase II Study of the National Cancer Institute of Canada-Clinical Trials Group

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 422-428

  Trudeau, Maureen E ^a   Eisenhauer, Elizabeth A ^b   Higgins, Brian P ^b   Letendre, Francois ^b   Lofters, Wycliffe S ^b   Norris, Brian D ^b   Vandenberg, Theodore A ^b   Delorme, Fernand ^b   Muldal, Alison M ^b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPERSENSITIVITY REACTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOPENIA; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0030048914     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.422     Document Type: Article

References (29)

1. Clavel M, Catimel G: Breast cancer: Chemotherapy in the treatment of advanced disease. Eur J Cancer 29:4:598-604, 1993
2. Ringel I, Horwitt SB: Studies with RP 56976 (Taxotere): A semi-synthetic analogue of Taxol. J Natl Cancer Inst 83:288-29, 1991
3. Ise W, Hogg M, Sanders KH, et al: Reversal of resistance to Taxol and Taxotere by dexniguldipine-HCI: Dose dependent modulation in various human MDR cell lines. Proc Am Assoc Cancer Res 35:356, 1994 (abstr)
4. Bissery MC, Guenard D, Gueritte-Voegelein F, et al: Experimental antitumour activity of Taxotere (RP 56976; NSC 628503), a Taxol analogue. Cancer Res 51:4845-4852, 1991
5. Burris H, Irvin R, Kuhn J, et al: Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 11:950-958, 1993
6. Extra JM, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037-1042, 1993
7. Pazdur R, Newman RA, Newman BM, et al: Phase I trial of Taxotere: Five-day schedule. J Natl Cancer Inst 84:781-188, 1993
8. Tomiak E, Piccart MJ, Kerger J, et al: A phase I study of Taxotere (RP 56976, NSC 628503) administered as a one hour intravenous (IV) infusion on a weekly basis. Eur J Cancer 27:S194, 1991 (suppl 2; abstr 1184)
9. Bisset D, Seranoians A, Cassidy J, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53:523-527, 1993
10. Aapro MS, Zulian G, Alberto P, et al: Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of Taxotere. Ann Oncol 3:53, 1992 (suppl 5; abstr 208)
11. Irvin B, Burris H, Kuhn J, et al; Phase I trial of a 2 and 3 hour infusion of Taxotere. Proc Am Soc Clin Oncol 12:137, 1993 (abstr 347)
12. Holmes FA, Walters RS, Theriault RI, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
13. Reichman BS, Seidman A, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
14. Fumoleau P, Chevallier B, Kerbrat P, et al: First line chemotherapy with Taxotere (T) in advanced breast cancer (ABC): A phase II study of the EORTC Clinical Screening Group (CSG). Proc Am Soc Clin Oncol 12:56, 1993 (abstr)
15. Seidman AD, Hudis C, Crown JPA, et al: Phase II evaluation of Taxotere (RP56976, NSC 628503) as initial chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 12:63, 1993 (abstr)
16. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment for Cancer. J Clin Oncol 13:314-322, 1995
17. Dieras V, Fumoleau P, Chevallier B, et al: Second EORTC-Clinical Screening Group (CSG) phase II trial of Taxotere (docetaxel) as first line chemotherapy (CT) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 13:78, 1994 (abstr 115)
18. Krakowsky I, Rios M, Fumoleau P, et al: Phase II first line chemotherapy (CT) study with docetaxel (Taxotere) and prophylactic premedication of fluid retention (FR) in patients (pts) with metastatic (mts) or locally advanced breast cancer (ABC). Proc Am Soc Clin Oncol 14:97, 1995 (abstr 87)
19. ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase II trial of docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5:527-532, 1994
20. Rhone-Poulenc Rorer: Data on file. Antony, France, International Registration Department, 1994
21. Valero V, Walters R, Theriault R, et al: Phase II study of Taxotere in refractory metastatic breast cancer (RMBC). Eur J Cancer 29A:6:S83, 1993 (suppl 6; abstr 437)
22. Ravdin PM, Burris SM, Cooke G, et al: Phase II evaluation of Taxotere (RP56976) as chemotherapy for anthracycline refractory metastatic breast cancer. Ann Oncol 5:203, 1994 (suppl 5; abstr 512)
23. Nabholtz JM, Gelmon K, Dontenbal M, et al: Randomized trial of two doses of Taxol in metastatic breast cancer: An interum analysis. Proc Am Soc Clin Oncol 12:60, 1993 (abstr 42)
24. Seidman A, Crown J, Reichman B, et al: Lack of clinical cross-resistance of Taxol (T) with anthracycline (A) in the treatment of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 12:63, 1993 (abstr 53)
25. Holmes FA, Valero V, Theriault RL, et al: Phase II trial of Taxol (T) in metastatic breast cancer (MBC) refractory to multiple prior treatments. Proc Am Soc Clin Oncol 12:94, 1993 (abstr 178)
26. Ravdin PM, Valero V: Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. Semin Oncol 22:17-21, 1995
27. ten Bokkel Huinink WW, Van Oosterom AT, Piccart M, et al: Taxotere in advanced breast cancer: A phase II trial of the EORTC Early Clinical Trials Group. Proc Am Soc Clin Oncol 12:70, 1993 (abstr)
28. Schrijvers D, Wanders J, Dirix L, et al: Coping with toxicities of docetaxel (Taxotere). Ann Oncol 4:610-611, 1993
29. Valero V, Walters R, Theriault R, et al: Phase II study of docetaxel (Taxotere) in anthracycline-refractory metastatic breast cancer (ARMBC). Proc Am Soc Clin Oncol 13:470, 1994 (abstr)